Company: Johnson & Johnson's Centocor, Schering-Plough
Scoop: Golimumab is a human monoclonal antibody for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is being studied as an every four week subcutaneous injection as well as an intravenous infusion therapy. If approved, golimumab would join the ranks of such anti-TNF blockbusters as Enbrel, Humira and J&J's own Remicade. Golimumab's advantage? The drug requires injections only once a month, compared to higher frequencies for other existing drugs. The companies submitted an NDA for the drug in both the U.S. and Europe last month.